Prudential Financial’s Akero Therapeutics AKRO Stock Holding History

Prudential Financial’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-79,245	Closed	-$3.76M	–	2216
2025 Q3	$3.76M	Sell	79,245 -7,245	-8%	-$351K	﹤0.01%	1072
2025 Q2	$4.62M	Buy	86,490 +48,055	+125%	+$2.18M	0.01%	943
2025 Q1	$1.56M	Buy	+38,435	New	+$1.63M	﹤0.01%	1400

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prudential Financial's AKRO Position: Q4 2025 in Review

Prudential Financial sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 79,245 shares — an estimated $3.76M sold.

Prudential Financial first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $4.62M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Prudential Financial reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Prudential Financial sold 79,245 Akero Therapeutics shares in Q4 2025, an estimated $3.76M.
Prudential Financial first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
Prudential Financial's Akero Therapeutics position peaked at $4.62M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Prudential Financial's 13F filing for Q4 2025, filed 13 Feb 2026.